These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 10670395)

  • 21. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
    Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B
    Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of direct-to-consumer advertising of hydroxymethylglutaryl coenzyme a reductase inhibitors on attainment of LDL-C goals.
    Bradford WD; Kleit AN; Nietert PJ; Ornstein S
    Clin Ther; 2006 Dec; 28(12):2105-18; discussion 2104. PubMed ID: 17296467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of a stanol-enriched diet on plasma cholesterol and triglycerides in patients treated with statins.
    Castro Cabezas M; de Vries JH; Van Oostrom AJ; Iestra J; van Staveren WA
    J Am Diet Assoc; 2006 Oct; 106(10):1564-9. PubMed ID: 17000189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
    Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ezetimibe in the treatment of uncontrolled hyperlipidemia in kidney transplant patients.
    Rodríguez-Ferrero ML; Anaya F
    Transplant Proc; 2008 Dec; 40(10):3492-5. PubMed ID: 19100421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
    Schuster H; Barter PJ; Stender S; Cheung RC; Bonnet J; Morrell JM; Watkins C; Kallend D; Raza A;
    Am Heart J; 2004 Apr; 147(4):705-13. PubMed ID: 15077101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and cost outcomes of medical nutrition therapy for hypercholesterolemia: a controlled trial.
    Delahanty LM; Sonnenberg LM; Hayden D; Nathan DM
    J Am Diet Assoc; 2001 Sep; 101(9):1012-23. PubMed ID: 11573752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
    Miller PS; Smith DG; Jones P
    Am J Cardiol; 2005 Jun; 95(11):1314-9. PubMed ID: 15904635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.
    Devroey D; Velkeniers B; Duquet W; Betz W
    Int J Cardiol; 2005 May; 101(2):231-5. PubMed ID: 15882669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation.
    Ansell BJ; Watson KE; Weiss RE; Fonarow GC
    Heart Dis; 2003; 5(1):2-7. PubMed ID: 12549983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14).
    Spanheimer R; Betteridge DJ; Tan MH; Ferrannini E; Charbonnel B;
    Am J Cardiol; 2009 Jul; 104(2):234-9. PubMed ID: 19576353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensive nutrition counseling enhances outcomes of National Cholesterol Education Program dietary therapy.
    Rhodes KS; Bookstein LC; Aaronson LS; Mercer NM; Orringer CE
    J Am Diet Assoc; 1996 Oct; 96(10):1003-10; quiz 1011-2. PubMed ID: 8841162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of pravastatin in patients with primary hyperlipidaemia.
    Mafauzy M; Mokhtar M; Wan Mohamad WB; Musalmah M
    Med J Malaysia; 1995 Sep; 50(3):272-7. PubMed ID: 8926908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia.
    Mostaza JM; Schulz I; Vega GL; Grundy SM
    Am J Cardiol; 1997 May; 79(9):1298-301. PubMed ID: 9164913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
    Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC
    Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.